Open Journal Systems

Effects of Neoadjuvant Chemotherapy on Multiple Cytokines in Patients with Tri-negative Breast Cancer

Adam R Botha (Myriad International GmbH, Cologne, Germany)


The novel ET therapy is that doxorubicin and paclitaxel are used in neoadjuvant chemotherapy for tri-negative breast cancer (TNBC). The study mainly investigated the efficacy of ET therapy and its impact on tumor markers and cytokines. Firstly extracted from August 2017 to August 2020, 84 cases of TNBC patients were as experimental group in our hospital, and the patients were randomly divided into two groups, including the control group (42 cases) underwent conventional chemotherapy and observation group (42 cases) to accept ET neoadjuvant chemotherapy. To compare the therapeutic effect of two groups, levels of cytokines, tumor markers, and survival were detected. The results showed that the total efficiency of the control group was 80.95%, significantly lower than that of the observation group (95.24%), and the difference between the two groups was statisticallysignificant (P<0. 05). The survival rate of the control group was 78.57%, which was significantly lower than that of the observationgroup (95.24%). In addition, CEA, CA19-9, CA125 and VEGF of the control group were significantly higher than those of theobservation group (P<0. 05). Therefore, the ET therapy of neoadjuvant chemotherapy has an ideal effect on the treatment of TNBC,which can reduce the levels of tumor markers and cytokines, prolonging the survival rate of patients.


ET neoadjuvant chemotherapy; Tri-negative breast cancer tumor; Marker cytokines

Full Text:



Han RB, Ren Y. Effects of neoadjuvant chemotherapy on sex hormones and serum cytokines in postmenopausal breast cancer patients [J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2008, 25(4) : 45-48.

Liu XB, Huang GX. Changes of cytokines and serum tumor markers in elderly breast cancer patients [J]. Journal of Hainan Medical University, 2012, 212(13) : 71-73.

Luo FM Tang BL, Zou XL. Effect of autologous DC-CIK cell therapy on postoperative immune function of patients with triple negative breast cancer [J]. Chinese Journal of Oncology Clinical And Rehabilitation, 2017, 24(8) : 967-970.

Sun P. Effect of breast conserving surgery on serum markers, NK cells, CD19~+ cells and postoperative recurrence in breast cancer patients [J]. Journal of Practical Clinical Medicine, 2012, 22(15) : 59-62.

Guo ZH, Hu QL, Zhou Q, et al. Changes and clinical significance of serum tumor markers, cytokines and sialic acid levels in patients with breast disease [J]. Advances in modern biomedicine, 2017,17 (33) : 6549-6552.

Li XG, Liu JX. Effect of cancer combined with neoadjuvant chemotherapy on the expression of proliferative molecules and immune function in breast cancer patients [J]. Journal of hai nan medical college, 2017,23 (22) : 3096-3099.

Chen LJ. Clinical efficacy of bevacizumab combined with TP regimen in the treatment of advanced HER2-negative breast cancer and its influence on the level of related cytokines in patients [J]. Marker immunoanalysis and Clinical Practice, 2012, 141(7) : 49-51, 72.

Zheng TZ, Pang ZY, Zhang Q. Short-term efficacy of docetaxel combined with epirubicin in the treatment of locally advanced breast cancer and its effect on serum tumor markers [J]. Cancer Progression, 2016, 16(15) : 70-73.



  • There are currently no refbacks.

Copyright (c) 2020 Adam R Botha

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.